TipRanks
Go Ultimate55% OFF

Compare Ottobock SE & Co. KGaA (OBCKF) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
OBCKFOttobock SE & Co. KGaA$8,536.90$3.44B―0.00%Strong BuyUnlock the OBCKF analyst price target with TipRanks PremiumOBCKFUnlock the OBCKF top-analyst price target with TipRanks Premium
DE:AFXCarl Zeiss MeditecEUR 34.78EUR 3.13B20.95-19.77%Moderate SellUnlock the DE:AFX analyst price target with TipRanks PremiumOBCKF vs DE:AFXUnlock the DE:AFX top-analyst price target with TipRanks Premium
DE:COPCompuGroup MedicalEUR 28.45EUR 1.50B43.4216.12%―Unlock the DE:COP analyst price target with TipRanks PremiumOBCKF vs DE:COPUnlock the DE:COP top-analyst price target with TipRanks Premium
DE:DRW3Draegerwerk AG & Co. KGaAEUR 102.00EUR 1.64B11.2837.28%―Unlock the DE:DRW3 analyst price target with TipRanks PremiumOBCKF vs DE:DRW3Unlock the DE:DRW3 top-analyst price target with TipRanks Premium
DE:EUZEckert & Ziegler Strahlen und MedizintechnikEUR 13.37EUR 832.23M16.63-21.76%Moderate BuyUnlock the DE:EUZ analyst price target with TipRanks PremiumOBCKF vs DE:EUZUnlock the DE:EUZ top-analyst price target with TipRanks Premium
DE:SBSSTRATEC BiomedicalEUR 23.90EUR 273.51M-562.50-0.44%Moderate BuyUnlock the DE:SBS analyst price target with TipRanks PremiumOBCKF vs DE:SBSUnlock the DE:SBS top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
OBCKFOttobock SE & Co. KGaA8536.900.000.00%
DE:AFXCarl Zeiss Meditec34.98-7.07-16.82%
DE:COPCompuGroup Medical28.454.3017.83%
DE:DRW3Draegerwerk AG & Co. KGaA102.0031.8245.34%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik13.30-3.09-18.88%
DE:SBSSTRATEC Biomedical22.500.321.43%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts